2023 Annual Summit on Hematologic Cancers: Incorporation of Novel Therapies in Clinical Practice

Nashville, TN US
September 15, 2023 to September 17, 2023

This CME-accredited activity 2023 Annual Summit on Hematologic Cancers features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.

Target Audience

  • Cancer care professionals
  • Practicing medical oncologists/hematologists
  • Radiation oncologists
  • Pathologists
  • Medical oncology and hematology fellows
  • Oncology nurses
  • Nurse practitioners
  • Physician assistants
  • Pharmacists

HOTEL RESERVATIONS

A limited number of guestrooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night. Reservations by attendees must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate. Individual Reservations for the Event will be made by individual attendees directly with Marriott reservations at (877) 351-5021.

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review strategies for initial therapy and therapies for relapsed disease for patients with various hematologic malignancies
  • Outline efficacy and toxicities of small molecule inhibitors, monoclonal antibodies, antibody drug conjugates, T-cell redirecting bispecific antibodies, and CAR-T for the treatment of patients with hematologic malignancies
  • Apply an individualized treatment plan for patients with ALL, AML, CML, MPN, MM, NHL, HL, based on patient- and disease-related factors 
  • Review evolving role of autologous and allogeneic stem cell transplantation in different hematologic malignancies

ABSTRACT SUBMISSION INFORMATION

Submit your abstract to present at this meeting on September 15 to 17, 2023, at the Gaylord Opryland Resort & Convention Center in Nashville, TN. 

The Abstract Submission Deadline is June 30th, 2023.

We will accept abstracts in the following categories. Please select a category that fits the submission best when submitting the abstract:

  • Basic science research
  • Clinical research
  • Quality-of-care research
  • Outcomes research
  • Case reports and case-series 

Notifications – Authors will be notified of acceptance or rejection via email.

ABSTRACT AWARD:

The top three highest-scoring abstracts submitted by residents or fellows will receive complimentary registration and two free hotel nights during the conference. A resident/fellow/trainee must be the abstract's first author.

SUBMIT YOUR ABSTRACT HERE

Course summary
Available credit: 
  • 12.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 12.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 12.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.75 Contact Hours.
Course opens: 
01/17/2023
Course expires: 
10/17/2023
Event starts: 
09/15/2023 - 1:30pm PDT
Event ends: 
09/17/2023 - 12:00pm PDT
Cost:
$450.00
Add to calendar: 

Conference chairs: Nitin Jain, MD, Navneet Majhail, MD, MS, Shaji Kumar, MD, & Sonali Smith, MD

 

Day 1 - September 15, 2023

12:00 PM - 01:00 PM: REGISTRATION, EXHIBITS, & SOCIALIZE

01:00 PM - 01:30 PM: OPENING REMARKS

01:30 PM - 03:00 PM: SESSION 1: ALL

Chairs: Lori Muffly, MD, MS & Nitin Jain, MD 

01:30 PM - 01:45 PM: How do I incorporate CAR T in my clinical practice?- Wendy Stock, MD, MA

01:45 PM - 02:00 PM: Anything new in T-ALL therapy? - Bijal Shah, MD

02:00 PM -03:00 PM: Case-Based Panel Discussion- Minoo Battiwalla MD, MS

03:00 PM – 03:30 PM: BREAKS & EXHIBITS

03:30 PM – 05:00 PM: SESSION 2: AGGRESSIVE LYMPHOMAS

Chairs: Nirav Shah, MD, MPH & Sairah Ahmed, MD

03:30 PM - 03:45 PM: Sequencing of CAR-T- Olalekan O. Oluwole, M.B.B.S., M.D.

03:45 PM - 04:00 PM: Focus on elderly patients and CAR-T- Sairah Ahmed, MD

04:00 PM - 05:00 PM: Case-Based Discussion 

05:00 PM - 06:00 PM: ABSTRACT SESSION

 

Day 2 - September 16

07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCALIZE

07:30 AM – 08:15 AM: INDUSTRY SPONSORED SYMPOSIA

08:30 AM – 10:00 AM: SESSION 3: MULTIPLE MYELOMA – NEWLY Dx

Chairs: Muzaffar H. Qazilbash, MD & Noopur Raje, MD

08:30 AM - 08:45 AM: Triplets or quadruplets – what is the right approach for newly diagnosed MM? - Noopur Raje, MD

08:45 AM - 09:00 AM: Transplant for MM – does it still have a role? - Muzaffar H. Qazilbash, MD

09:00 AM - 09:15 AM: Maintenance approaches for MM – one drug or two? - Shaji Kumar, MD

09:15 AM - 10:00 AM: Case- Based Discussion

10:00 AM – 10:30 AM: BREAKS & EXHIBITS

10:30 AM – 12:00 PM: SESSION 4: AML/MDS

Chairs: Stephen Strickland, MD, MSC, Alexander Perl, MD

10:30 AM - 10:45 AM: Frontline Therapy of AML in 2023 - Tapan Kadia, MD

10:45 AM - 11:00 AM: Updates in treatment of MDS - Hetty Carraway, MD

11:00 AM - 11:20 AM: ICC vs. WHO: Clash of the Titans- Sanam Loghavi, MD

11:20 AM - 12:00 PM: Case- Based Discussion- Somedeb Ball, MD

12:00 PM - 12:45 PM: LUNCH, EXHIBITS & INDUSTRY SPONSORED SYMPOSIA  

01:00 PM - 01:30 PM: (KEYNOTE) TREATMENT OF HODGKIN LYMPHOMA IN 2023 - Ranjana H. Advani, MD

01:30 PM - 03:00 PM: SESSION 5: CLL

Chairs: Nitin Jain, MD & Jacqueline Barrientos, MD, MS

01:30 PM - 01:45 PM: BTK or BCL2i or Both for Frontline CLL- Mazyar Shadman, MD, MPH

01:45 PM - 02:00 PM: Pirtobrutinib, CAR T, and others. How to incorporate it in practice?- Bill Wierda, MD, PhD

02:00 pm - 02:20 PM: Richter transformation. What’s new?- Sameer A Parikh, MBBS

02:20 PM - 03:00 PM: Case- Based Discussion 

03:00 PM – 03:30 PM: BREAKS & EXHIBITS

03:30 PM – 05:00 PM: SESSION 6: LOW-GRADE LYMPHOMAS

Chairs: Sonali Smith, MD & Michael Tees, MD

03:30 PM - 03:45 PM: Are bi-specifics really going to have a role in indolent lymphomas?- Brian T. Hill, MD, PhD

03:45 PM - 04:00 PM: Sequencing of treatments in 2L+ settings- Loretta Nastoupil, MD

04:00 PM - 05:00 PM: Case- Based Panel Discussion

 

Day 3 - September 17

07:00 AM - 08:00 AM: REGISTRATION, EXHIBITS, & SOCIALIZE

07:30 AM - 08:15 AM: INDUSTRY SPONSORED SYMPOSIA

Keynote Talk: 

08:15 AM- 08:45 AM:  Precision Medicine in Oncology- Vivek Subbiah, MD

08:45 am - 10:00 AM: SESSION 7: CML/MPN

Chairs: Gabriela Hobbs, MD & Naveen Pemmaraju, MD

08:45 AM - 09:00 AM: Incorporating novel JAKi and other therapies in MF management- Ashwin Kishtagari, MD

09:00 AM - 09:15 AM: Unanswered questions in CML in 2023- Jorge Cortes, MD

09:15 AM - 09:30 AM: Advanced MPN. Unanswered questions- Anand Patel, MD

09:30 AM -10:10 AM: Case- Based Discussion- Srinivas Tantravahi, MD

10:10 AM - 10:30 AM: BREAKS & EXHIBITS

10:30 AM - 12:00 PM: SESSION 8: MULTIPLE MYELOMA – R/R

Chairs: Shaji Kumar, MD & Natalie Callander, MD

10:30 AM - 10:45 AM: Management of early relapses in myeloma-choosing the right combination - Natalie Callander, MD

10:45 am - 11:00 AM: Integrating immunotherapies into the treatment of relapsed MM – CART, ADC, and bispecifics - Jesus Berdeja, MD

11:00 AM - 11:15 AM: Non-immune approaches for advanced myeloma - Ajay Nooka, MD, MPH, FACP

11:15 AM - 12:00 PM: Case- Based Discussion 

12:15 PM: ADJOURN

Gaylord Opryland Resort & Convention Center
2800 Opryland Dr
Nashville, TN 37214
United States

Guest room reservation

A limited number of guest rooms have been reserved at the Gaylord Opryland Hotel for participants of this meeting at the discounted nightly single/double rate of $319/night. 

Reservation cut-off: 

Reservations must be made on or before 5 PM CST on Friday, August 8, 2023, to receive the discounted room rate.

Applicable taxes will be added to room rates (currently 9.25% State Tax, 6% Occupancy Tax and $2.50 City Tax). Rates quoted are for single/double occupancy. Each additional person to a room is $20.00. 

Children twelve (12) years and under are free when occupying the same room as their parents. Atrium view upgrades are an additional $60.00.

RESERVATION METHOD:

Reservations must be made directly with Marriott reservations at (877) 351-5021 or follow the link below to receive the discounted rate.

Room reservation Link -   

https://book.passkey.com/go/NashvilleHematology2023

RESORT FEE: The prevailing resort fee, currently $25.00 plus applicable taxes, will be added to the guest room rate. This fee will cover several in-room amenities which at the time of check-in will include: 

  • Resort Wide Internet Access to include: Enhanced in-room wireless Internet Access for up to six (6) devices and Basic Wireless Internet Access in Public Areas and Convention Center on a Shared Network

  • Unlimited local and long-distance calls

  • Daily shuttle service to Opry Mills and The Inn at Opryland

  • Shuttle transportation to scheduled Grand Ole Opry and General Jackson Showboat performances

  • Bottled water (2 daily) replenished once daily with housekeeping service

  • Daily credit of up to $10 per room toward dry cleaning (credit is not cumulative through stay)

  • Transportation to Gaylord Springs Golf Links, practice range access and daily bucket of balls (rental club provided; appropriate attire required)

 

Travel

Parking

The parking fee is currently $33.00 plus tax for self-parking and $45.00 plus tax for valet parking. The hotel will provide $10 off the currently prevailing parking rate to the attendees of the conference. Attendees are responsible for covering the costs of parking themselves.

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTEREST:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Course Director(s)

Nitin Jain, MD

has a financial relationship (Gift) with Pharmacyclics;.
has a financial relationship (Gift) with AstraZeneca;.
has a financial relationship (Gift) with Cellectis;.
has a financial relationship (Gift) with Genentech;.
has a financial relationship (Gift) with Beigene;.
has a financial relationship (Gift) with AbbVie;.
has a financial relationship (Gift) with Precision Bio;.
has a financial relationship (Gift) with Janssen;.
has a financial relationship (Gift) with Kite;.
has a financial relationship (Gift) with Fate Therapeutics;.

Shaji Kumar, MD

has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.
has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.

Navneet Majhail, MD, MS, FASTCT

has a financial relationship (Independent contractor) with Anthem Inc;.
has a financial relationship (Independent contractor) with Incyte;.

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Moderator(s)

Sairah Ahmed, MD

has a financial relationship (Professional Services) with Chimagen;.
has a financial relationship (Professional Services) with ADCT;.
has a financial relationship (Professional Services) with Tessa ;.
has a financial relationship (Professional Services) with myeloid;.

Gabriela Hobbs, MD

has a financial relationship (Financial Support) with Novartis;.
has a financial relationship (Financial Support) with Cogent;.
has a financial relationship (Financial Support) with Abbvie;.
has a financial relationship (Financial Support) with Pharmaxis;.
has a financial relationship (Financial Support) with BMS;.
has a financial relationship (Financial Support) with Incyte;.
has a financial relationship (Financial Support) with Pfizer;.
has a financial relationship (Financial Support) with Morphosys;.

Nirav Shah, MD

has a financial relationship (Independent contractor) with Miltenyi Biotec;.
has a financial relationship (Independent contractor) with BMS-Juno;.
has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Loxo-Lilly;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Stock) with Tundra Therapeutics;.
has a financial relationship (Independent contractor) with Incyte;.
has a financial relationship (Independent contractor) with TG Therapeutics;.
has a financial relationship (Independent contractor) with Kite;.
has a financial relationship (Independent contractor) with Seattle Genetics;.
Planner(s)

Binay Shah, MD, MHA

has no relevant financial relationships to disclose at this time.
Speaker(s)

Ranjana Advani, Professor of Medicine at Stanford University

has a financial relationship (Financial Support) with Daiichi;.
has a financial relationship (Other) with Incyte;.
has a financial relationship (Other) with BeiGene;.
has a financial relationship (Financial Support) with Seattle Genetics;.
has a financial relationship (Other) with Daiichi;.
has a financial relationship (Other) with ADCT;.
has a financial relationship (Financial Support) with Regeneron;.
has a financial relationship (Financial Support) with Merck;.
has a financial relationship (Financial Support) with Gilead;.
has a financial relationship (Other) with Epizyme;.
has a financial relationship (Financial Support) with Conjupro;.
has a financial relationship (Financial Support) with Cyteir;.
has a financial relationship (Other) with Bristol Myers Squibb/Celgene;.
has a financial relationship (Other) with Genentech/Roche;.

Jesus Berdeja

has a financial relationship (Professional Services) with Legend Biotech;.
has a financial relationship (Grant Or Contract) with Abbvie;.
has a financial relationship (Grant Or Contract) with C4 Therapeutics;.
has a financial relationship (Grant Or Contract) with Fate Therapeutics;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Professional Services) with Celgene;.
has a financial relationship (Professional Services) with Kite Pharma;.
has a financial relationship (Grant Or Contract) with 2Seventy Bio;.
has a financial relationship (Grant Or Contract) with BMS;.
has a financial relationship (Grant Or Contract) with Celularity;.
has a financial relationship (Grant Or Contract) with Ichnos Sciences;.
has a financial relationship (Grant Or Contract) with Sanofi;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Takeda;.
has a financial relationship (Grant Or Contract) with Amgen;.
has a financial relationship (Grant Or Contract) with Cartesian Therapeutics;.
has a financial relationship (Grant Or Contract) with GSK;.
has a financial relationship (Grant Or Contract) with Karyopharm;.
has a financial relationship (Professional Services) with Bluebird;.
has a financial relationship (Professional Services) with Roche;.
has a financial relationship (Grant Or Contract) with Acetylon;.
has a financial relationship (Grant Or Contract) with CARsgen;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Grant Or Contract) with Zentalis;.
has a financial relationship (Professional Services) with CRISPR Therapeutics;.

Natalie Callander

has no relevant financial relationships to disclose at this time.

Jorge Cortes, MD

has a financial relationship (Other) with Pfizer;.
has a financial relationship (Other) with Novartis;.
has a financial relationship (Other) with Sun Pharma;.
has a financial relationship (Other) with Abbvie;.
has a financial relationship (Other) with Takeda;.

Brian Hill, MD, PhD

has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Pharmacyclics;.
has a financial relationship (Independent contractor) with Genmab;.
has a financial relationship (Independent contractor) with Gilead;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Beigene;.

Sanam Loghavi, Associate Professor

has a financial relationship (Professional Services) with QualWorld;.
has a financial relationship (Professional Services) with Caris ;.
has a financial relationship (Professional Services) with Guidepoint;.
has a financial relationship (Professional Services) with Daiichi Sankyo;.
has a financial relationship (Stock) with Abbvie ;.
has a financial relationship (Professional Services) with Abbvie ;.
has a financial relationship (Professional Services) with OncLive;.
has a financial relationship (Professional Services) with GLG;.
has a financial relationship (Travel) with Mission Bio ;.

Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service

has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with AbbVie;.
has a financial relationship (Grant Or Contract) with Sumitumo;.
has a financial relationship (Grant Or Contract) with Kronos Bio;.
has a financial relationship (Grant Or Contract) with Pfizer;.

Mazyar Shadman, MD,MPH

has a financial relationship (Professional Services) with MorphoSys/Incyte;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with TG Therapeutics;.
has a financial relationship (Professional Services) with Genmab;.
has a financial relationship (Professional Services) with Mustang Bio ;.
has a financial relationship (Professional Services) with AbbVie;.
has a financial relationship (Professional Services) with Genentech;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Employment) with BMS;.
has a financial relationship (Professional Services) with Pharmacyclics;.
has a financial relationship (Professional Services) with BeiGene;.

Available Credit

  • 12.75 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12.75 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 12.75 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 12.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 12.75 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 12.75 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 12.75 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$450.00
Please login or register to take this course.

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.